©bongkarn thanyakij via Canva.com
HCT/P Donor Compliance Risks: Best Practices for Testing, Screening and Determining Eligibility
This Webinar is over| Date | May 28, 2015 |
| Time | 12:30 PM EDT |
| Cost | $287.00 |
|
Online
|
The FDA has been busy enforcing 21 CFR part 1271, subpart C which requires human cells, tissues, and cellular and tissue-based product (HCT/P) establishments to properly determine donor-eligibility, including donor screening and testing.
HCT/Ps must not be transferred, implanted, transplanted or infused until the donor has been determined to be eligible.
FDAnews has partnered with David Smith of Pepper Hamilton for an analysis of the FDA’s current inspection and enforcement actions regarding 21 CFR part 1271, subpart C which requires human cells, tissues, and cellular and tissue-based product (HCT/P) establishments to properly determine donor-eligibility, including donor screening and testing. David — recognized as an industry expert in HCT/P donor eligibility and tissue ownership issues — will detail how HCT/P establishments can self-audit and assure they will not be in the FDA’s cross-hairs during their next inspection.
During this 90 minute presentation attendees will learn:
• What the most common red flags FDA investigators look for as they inspect your files during an inspection
• Best practices for testing suspect HCT/P product to assure it is ready for release
• Tips for creating eligibility screening checklists that match the requirements of 21 CFR part 1271, subpart C
• Who should be involved in the decision making — and what documentation should exist — when releasing a previously quarantined product
• How to write SOPs that teach employees the importance of and proper action when dealing with departures from procedures situations. This is a common FDA inspectional observation finding.
• How the FDA expects a “responsible person” to act on issues where there are concerns about product eligibility or risks of communicable disease transmission. Should this person be an employee, independent outsider or a committee?
Who Will Benefit:
This course will benefit:
• Medical affairs professionals
• Regulatory affairs professionals
• Compliance personnel
• QA/QC personnel
• Senior management
• In-house and outside counsel
• Professionals new to HCT/Ps
Conference Details:
HCT/P Donor Compliance Risks:
Best Practices for Testing, Screening and Determining Eligibility
**FDAnews Webinar**
May 28, 2015 — 1:30 p.m. – 3:00 p.m. EDT
www.fdanews.com/HCTPDonorCompliance
Easy Ways to Register:
Online: www.fdanews.com/HCTPDonorCompliance
By phone: 888-838-5578 or 703-538-7600
HCT/Ps must not be transferred, implanted, transplanted or infused until the donor has been determined to be eligible.
FDAnews has partnered with David Smith of Pepper Hamilton for an analysis of the FDA’s current inspection and enforcement actions regarding 21 CFR part 1271, subpart C which requires human cells, tissues, and cellular and tissue-based product (HCT/P) establishments to properly determine donor-eligibility, including donor screening and testing. David — recognized as an industry expert in HCT/P donor eligibility and tissue ownership issues — will detail how HCT/P establishments can self-audit and assure they will not be in the FDA’s cross-hairs during their next inspection.
During this 90 minute presentation attendees will learn:
• What the most common red flags FDA investigators look for as they inspect your files during an inspection
• Best practices for testing suspect HCT/P product to assure it is ready for release
• Tips for creating eligibility screening checklists that match the requirements of 21 CFR part 1271, subpart C
• Who should be involved in the decision making — and what documentation should exist — when releasing a previously quarantined product
• How to write SOPs that teach employees the importance of and proper action when dealing with departures from procedures situations. This is a common FDA inspectional observation finding.
• How the FDA expects a “responsible person” to act on issues where there are concerns about product eligibility or risks of communicable disease transmission. Should this person be an employee, independent outsider or a committee?
Who Will Benefit:
This course will benefit:
• Medical affairs professionals
• Regulatory affairs professionals
• Compliance personnel
• QA/QC personnel
• Senior management
• In-house and outside counsel
• Professionals new to HCT/Ps
Conference Details:
HCT/P Donor Compliance Risks:
Best Practices for Testing, Screening and Determining Eligibility
**FDAnews Webinar**
May 28, 2015 — 1:30 p.m. – 3:00 p.m. EDT
www.fdanews.com/HCTPDonorCompliance
Easy Ways to Register:
Online: www.fdanews.com/HCTPDonorCompliance
By phone: 888-838-5578 or 703-538-7600
Create your own event
Turn your passion into a business.
Turn your passion into a business.